{Reference Type}: Journal Article
{Title}: CD99 Expression and Prognostic Impact in Glioblastoma: A Single-Center Cohort Study.
{Author}: Rocca A;Giudici F;Donofrio CA;Bottin C;Pinamonti M;Ferrari B;Schettini F;Pineda E;Panni S;Cominetti M;D'Auria P;Bianchini S;Varotti E;Ungari M;Ciccarelli S;Filippini M;Brenna S;Fiori V;Di Mambro T;Sparti A;Magnani M;Zanconati F;Generali D;Fioravanti A;
{Journal}: Cells
{Volume}: 13
{Issue}: 7
{Year}: 2024 Mar 29
{Factor}: 7.666
{DOI}: 10.3390/cells13070597
{Abstract}: Glioblastoma is the most frequent and aggressive brain tumor in adults. This study aims to evaluate the expression and prognostic impact of CD99, a membrane glycoprotein involved in cellular migration and invasion. In a cohort of patients with glioblastoma treated with surgery, radiotherapy and temozolomide, we retrospectively analyzed tumor expression of CD99 by immunohistochemistry (IHC) and by quantitative real-time polymerase chain reaction (qRT-PCR) for both the wild type (CD99wt) and the truncated (CD99sh) isoforms. The impact on overall survival (OS) was assessed with the Kaplan-Meier method and log-rank test and by multivariable Cox regression. Forty-six patients with glioblastoma entered this study. Immunohistochemical expression of CD99 was present in 83%. Only the CD99wt isoform was detected by qRT-PCR and was significantly correlated with CD99 expression evaluated by IHC (rho = 0.309, p = 0.037). CD99 expression was not associated with OS, regardless of the assessment methodology used (p = 0.61 for qRT-PCR and p = 0.73 for IHC). In an exploratory analysis of The Cancer Genome Atlas, casuistry of glioblastomas CD99 expression was not associated with OS nor with progression-free survival. This study confirms a high expression of CD99 in glioblastoma but does not show any significant impact on survival. Further preclinical studies are needed to define its role as a therapeutic target in glioblastoma.